Preimplantation Genetic Testing Market is expected to grow at a CAGR of 10.1% during the forecasted period | Evolve Business Intelligence

As per the study initiated by Evolve Business Intelligence, the global Preimplantation Genetic Testing Market size accounted for USD 2.4 Billion in 2023, growing at a CAGR of 10.1% from 2023 to 2033. Preimplantation Genetic Testing (PGT) is a medical procedure used in assisted reproductive technology (ART) that involves the examination of embryos for genetic abnormalities before they are implanted into the uterus. This testing is typically performed during in vitro fertilization (IVF) to identify genetic disorders or chromosomal abnormalities in embryos, helping to select embryos with the best chance of developing into a healthy pregnancy.

Request/Download PDF Sample: https://report.evolvebi.com/index.php/sample/request?referer=OpenPR&reportCode=021918

Growing awareness about genetic disorders and the ability of PGT to prevent their transmission has led to increased acceptance of this technology among couples undergoing IVF. Women delaying childbirth are more prone to chromosomal abnormalities in their eggs, making PGT a valuable tool for older mothers seeking to enhance the chances of a successful pregnancy. Continuous advancements in genetic testing technologies, such as next-generation sequencing, have improved the accuracy and reliability of PGT, making it more attractive to both healthcare providers and patients. The increasing prevalence of genetic disorders and the desire of parents to have healthy offspring contribute to the demand for PGT services.

Key Players
Some of the major Preimplantation Genetic Testing Market players holding high market shares include Quest Diagnostics Incorporated; Natera, Inc.; COOPER SURGICAL, INC.; and Genea Pty Limited.; Invitae Corporation; Laboratory Corporation of America Holdings. These players use partnership and collaboration as a key strategy to gain significant market share to compete with market leaders. Some of the other major market players include Thermo Fisher Scientific Inc.; Bioarray S.L., Illumina, Inc.; Igenomix, RGI; F. Hoffmann-La Roche Ltd

For More Information: https://report.evolvebi.com/index.php/sample/request?referer=OpenPR&reportCode=021918

Segmental Analysis
Based on technology, the Preimplantation Genetic Testing market is segmented into Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescent In-Situ Hybridization (FISH), and Others. Next Generation Sequencing (NGS) technology offers high accuracy and the ability to detect a wide range of genetic abnormalities. Due to its advanced capabilities, NGS might be the most sought-after technology, potentially leading to the largest market share.

Based on product, the Preimplantation Genetic Testing market is a Reagents and Consumables, Instruments, and Software. Reagents and Consumables represent the materials directly consumed during the testing process. With a high demand for testing, this segment could see the largest market share.
Based on application, the Preimplantation Genetic Testing market is segmented into Chromosomal Abnormalities, X-linked Diseases, Embryo Testing, Aneuploidy Screening, HLA Typing, and Other Applications. Chromosomal Abnormalities is a broad category encompassing various genetic conditions. Due to the high prevalence of such abnormalities and the need for early detection, this application could hold the largest market share.

Key Region/ Countries Covered
• North America (US, Canada, Mexico)
• Europe (Germany, U.K., France, Italy, Spain, Russia, Nordic Countries, BeNeLux, Rest of Europe)
• Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Rest of Asia Pacific)
• Middle East and Africa (Saudi Arabia, UAE, Egypt, South Africa, Rest of MEA)
• Latin America (Mexico, Brazil, Argentina, Rest of Latin America)

Address
Evolve Business Intelligence
C-218, 2nd floor, M-Cube
Gujarat 396191
India
Email: sales@evolvebi.com
Website: https://evolvebi.com/

About EvolveBI
Evolve Business Intelligence is a market research, business intelligence, and advisory firm providing innovative solutions to challenging pain points of a business. Our market research reports include data useful to micro, small, medium, and large-scale enterprises. We provide solutions ranging from mere data collection to business advisory.
Evolve Business Intelligence is built on account of technology advancement providing highly accurate data through our in-house AI-modelled data analysis and forecast tool - EvolveBI. This tool tracks real-time data including, quarter performance, annual performance, and recent developments from Fortune's global 2000 companies.

This release was published on openPR.